Combination therapy for coronary artery disease

• US 20070185065A1
• Filed: 02/03/2006
• Published: 08/09/2007
• Est. Priority Date: 02/03/2006
• Status: Abandoned Application

• Current Assignee: Vikramjit Chhokar
• Original Assignee: Vikramjit Chhokar
• Inventors: Chhokar, Vikramjit
• Application Number:
  US11/346,703
• Publication Number:
  US 20070185065A1
• Time in Patent Office: Days
• US Class Current: 514/160
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/4743 condensed with ring systems having sulfur as a ring hetero atom
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A combination therapy and methods for administering the combination therapy is provided that reduces mortality or morbidity of coronary artery disease (CAD) or coronary artery disease equivalents in individuals. The combination therapy can be administered to an individual in various forms, and the therapy is a medicament combining an anti-platelet agent(s), a beta-blocker, renin-angiotensin-aldosterone system (RAAS) inhibitor(s), and/or cholesterol modifying agent(s).

Claims

1. A method for the reduction of either mortality/death or morbidity/complications related to coronary artery disease (CAD) or CAD equivalent comprising the step of administrating to a patient an effective amount of a combined therapy, to treat multiple pathophysiologies that contribute to CAD, which comprises an anti-platelet agent, a beta blocker, an inhibitor of the renin-angiotensin-aldosterone system (RAAS) and/or a cholesterol modifying agent.

2. The method of claim 1 comprising administrating each of the components of the combined therapy simultaneously.

3. The method of claim 2 comprising administrating each of the components of the combined therapy in a single dosage form.

4. The method of claim 3 wherein the dosage form is selected from the group consisting of:

an oral dosage form, a parenteral dosage form, an intravenous dosage form, a rectal dosage form and an inhalation dosage form.

5. The method of claim 1 comprising administering each of the components of the combined therapy separately.

6. The method of claim 5 further comprising the steps of:

a) administering a first component of the combined therapy;

b) administering a second component of the combined therapy;

c) administering a third component of the combined therapy; and

d) administering a fourth component of the combined therapy.

7. The method of claim 5 comprising administering each of the components of the combined therapy in separate dosage forms.

8. The method of claim 7 wherein the dosage forms are selected from the group consisting of:

an oral dosage form, a parenteral dosage form, an intravenous form, a rectal dosage form and an inhalation dosage form.

9. The method of claim 1 wherein the RAAS inhibitor is selected from the group consisting of an ACE inhibitor, an ARB and/or an aldosterone blocker.

10. The method of claim 9 where the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat, spirapril or a pharmaceutically acceptable derivative thereof.

11. The method of claim 9 where the ARB is selected from the group consisting of saralasin acetate, candesartan cilexetil, valsartan, candesartan, losartan potassium, eprosartan, irbesartan, tasosartan, telmisartan or a pharmaceutically acceptable derivative thereof.

12. The method of claim 9 where the aldosterone blocker is selected from the group consisting of spironolactone, eplerenone or a pharmaceutically acceptable derivative thereof.

13. The method of claim 1 wherein the cholesterol-modifying agent is selected from the group consisting of an HMG-CoA synthase inhibitor, a squalene epoxidase inhibitor, a squalene synthetase inhibitor, an ACAT inhibitor, probucol, niacin, a fibrate, a cholesterol absorption inhibitor, a bile acid sequestrant, an LDL receptor inducer, an HDL modifier or a pharmaceutically acceptable derivative thereof.

14. The method of claim 1 wherein the antiplatelet agent is selected from the group consisting of aspirin, dipyridamole, clopidogrel, ticlopidine, glycoprotein IIb/IIIa inhibitors, cyclooxygenase inhibitor, ADP receptor blockers or a pharmaceutically acceptable derivative thereof.

15. The method of claim 1 wherein a beta blocker is selected from the group consisting of sotalol, timolol, esmolol, carteolol, carvedilol, nadolol, propranolol, propranolol, betaxolol, penbutolol, metoprolol, labetalol, acebutolol, atenolol, metoprolol, pindolol, bisoprolol or a pharmaceutically acceptable derivative thereof.

16. The method of claim 1 wherein the combined therapy contains 0.5 to 95% by weight of the components of the combined therapy.

17. A medication for use in the reduction of either the mortality/death or morbidity/complications related to coronary artery disease (CAD) or CAD equivalent comprising an effective amount of a combined therapy, to treat multiple pathophysiologies that contribute to CAD, including an anti-platelet agent(s), a beta blocker, an inhibitor(s) of the renin-angiotensin-aldosterone system (RAAS) and a cholesterol modifying agent.

18. A medication of claim 17 wherein a dosage form for the medication is selected from the group consisting of:

an oral dosage form, a parenteral dosage form, an Intravenous dosage form, a rectal dosage form, and an Inhalation dosage form.

19. The medication of claim 17 wherein the RAAS inhibitor is selected from the group consisting of an ACE Inhibitor, an ARB and/or an aldosterone blocker.

20. The medication of claim 19 where the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat, spirapril or a pharmaceutically acceptable derivative thereof.

21. The medication of claim 19 where the ARB is selected from the group consisting of saralasin acetate, candesartan cilexetil, valsartan, candesartan, losartan potassium, eprosartan, irbesartan, tasosartan, telmisartan or a pharmaceutically acceptable derivative thereof.

22. The medication of claim 19 where the aldosterone blocker is selected from the group consisting of spironolactone, eplerenone or a pharmaceutically acceptable derivative thereof.

23. The medication of claim 17 wherein the cholesterol-modifying agent is selected from the group consisting of an HMG-CoA synthase inhibitor, a squalene epoxidase inhibitor, a squalene synthetase inhibitor, an ACAT inhibitor, probucol, niacin, a fibrate, a cholesterol absorption inhibitor, a bile acid sequestrant, an LDL receptor inducer, an HDL modifier or a pharmaceutically acceptable derivative thereof.

24. The medication of claim 17 wherein the antiplatelet agent is selected from the group consisting of aspirin, dipyridamole, clopidogrel, ticlopidine, glycoprotein IIb/IIIa inhibitors, an cyclooxygenase inhibitor, ADP receptor blockers or a pharmaceutically acceptable derivative thereof.

25. The medication of claim 17 wherein a beta blocker is selected from the group consisting of sotalol, timolol, esmolol, carteolol, carvedilol, nadolol, propranolol, propranolol, betaxolol, penbutolol, metoprolol, labetalol, acebutolol, atenolol, metoprolol, pindolol, bisoprolol, or a pharmaceutically acceptable derivative thereof.

26. The medication of claim 17 wherein the combined therapy contains 0.5 to 95% by weight of the components of the combined therapy.

27. A method for the reduction of either the mortality/death or morbidity/complications related to coronary artery disease or CAD equivalent comprising the step of administrating to a patient an effective amount of combined therapy which includes two or more of:

an antiplatlet agent(s), beta blocker, inhibitor(s) of the renin-angiotensin-aldosterone system and/or cholesterol modifying agent(s) together with an additional medication useful in the treatment and prevention of coronary artery disease.

28. A medication for assisting a patient with coronary artery disease (CAD) or CAD equivalent in preventing the onset of future or recurrence of cardiovascular events such as stroke, congestive heart failure, cardiovascular death, myocardial infarction, worsening of angina, and cardiac arrest, the medication comprising the step of administrating to a patient an effective amount of combined therapy which includes two or more of:

an antiplatlet agent(s), beta blocker, inhibitor(s) of the renin-angiotensin-aldosterone system and/or cholesterol modifying agent(s) together with an additional medication useful in the treatment and prevention of coronary artery disease.

29. A medication for assisting a patient in preventing need for revascularisation procedures, such as coronary artery bypass graft surgery (CABG), Percutaneous Coronary Angioplasty (PTCA), peripheral angioplasty surgery, amputation, and carotid endarterectomy, the medication comprising the step of administrating to a patient an effective amount of combined therapy which includes two or more of:

an antiplatlet agent(s), beta blocker, inhibitor(s) of the renin-angiotensin-aldosterone system and/or cholesterol modifying agent(s) together with an additional medication useful in the treatment and prevention of coronary artery disease

30. A combination therapy medication that retards the progression of, or reverse CAD, the medication comprising an effective amount of two or more of:

an antiplatlet agent(s), beta blocker, inhibitor(s) of the renin-angiotensin-aldosterone system and/or cholesterol modifying agent(s) together with an additional medication useful in the treatment and prevention of coronary artery disease.

31. A method for halting or slowing the progression of atherosclerotic disease comprising the administration of a therapeutically effective amount of the medication of claim 30, to a person with atherosclerotic disease.

32. A method for preventing or reducing the risk of occurrence, or recurrence where the potential exists, of an atherosclerotic disease event comprising the administration of a therapeutically effective amount of the medication of claim 30, to a person at risk of having an atherosclerotic disease event.

33. A combination therapy medication that assists a patient in preventing diabetic complications such as overt nephropathy or new microalbuminuria, the medication comprising an effective amount of two or more of:

an antiplatlet agent(s), beta blocker, inhibitor(s) of the renin-angiotensin-aldosterone system and/or cholesterol modifying agent(s) together with an additional medication useful in the treatment and prevention of coronary artery disease